ECSP22064620A - COMPOSICIÓN INMUNOGÉNICA VIVA RECOMBINANTE QUE COMPRENDE EL VIRUS DE LA ENFERMEDAD DE NEWCASTLE (NDV) QUE EXPRESA LA SUBUNIDAD S1 Y EL RBD DE LA PROTEINA SPIKE DEL SARS-CoV-2 - Google Patents
COMPOSICIÓN INMUNOGÉNICA VIVA RECOMBINANTE QUE COMPRENDE EL VIRUS DE LA ENFERMEDAD DE NEWCASTLE (NDV) QUE EXPRESA LA SUBUNIDAD S1 Y EL RBD DE LA PROTEINA SPIKE DEL SARS-CoV-2Info
- Publication number
- ECSP22064620A ECSP22064620A ECSENADI202264620A ECDI202264620A ECSP22064620A EC SP22064620 A ECSP22064620 A EC SP22064620A EC SENADI202264620 A ECSENADI202264620 A EC SENADI202264620A EC DI202264620 A ECDI202264620 A EC DI202264620A EC SP22064620 A ECSP22064620 A EC SP22064620A
- Authority
- EC
- Ecuador
- Prior art keywords
- cov
- sars
- rbd
- subunit
- ndv
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Mycology (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente invención refiere a la obtención de dos vacunas vivas recombinantes o vectorizadas de NDV que expresan la subunidad S1 y RBD de la proteína S del SARS-CoV-2, que al ser aplicada por vía intranasal en modelo de animal hámster genera la producción de anticuerpos neutralizantes contra el SARS-CoV-2. La invención muestra además que estas vacunas vivas son compatibles para su uso combinado entre sí, para inducir la producción de anticuerpos neutralizantes contra el SARS-CoV-2 sin interferencia cruzada sustancial, lo que indica una sinergia entre ambas vacunas, en donde los virus recombinantes de NDV (rNDV-LS1-HN-RBD/SARS-CoV-2(SEQ ID No. 7) y rNDV-LS1-S1-F/SARS-CoV-2(SEQ ID No. 13)), logran expresar la subunidad S1 y RBD de la proteína S del SARS-CoV-2 en mamíferos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PE2021000033A PE20210318A1 (es) | 2021-01-08 | 2021-01-08 | Composicion inmunogenica viva recombinante que comprende el virus de la enfermedad de newcastle (ndv) que expresa la subunidad s1 y el rbd de la proteina spike del sars-cov-2 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP22064620A true ECSP22064620A (es) | 2022-09-30 |
Family
ID=74855966
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ECSENADI202264620A ECSP22064620A (es) | 2021-01-08 | 2022-08-17 | COMPOSICIÓN INMUNOGÉNICA VIVA RECOMBINANTE QUE COMPRENDE EL VIRUS DE LA ENFERMEDAD DE NEWCASTLE (NDV) QUE EXPRESA LA SUBUNIDAD S1 Y EL RBD DE LA PROTEINA SPIKE DEL SARS-CoV-2 |
Country Status (7)
Country | Link |
---|---|
AR (1) | AR124522A1 (es) |
BR (1) | BR112022016492A2 (es) |
CO (1) | CO2022010353A2 (es) |
EC (1) | ECSP22064620A (es) |
MX (1) | MX2022004220A (es) |
PE (1) | PE20210318A1 (es) |
WO (1) | WO2022149058A1 (es) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA016217B1 (ru) * | 2005-12-02 | 2012-03-30 | Маунт Синай Скул Оф Медсин | Химерные вирусы, представляющие неприродные поверхностные белки, и их применение |
WO2021229270A1 (es) * | 2020-05-13 | 2021-11-18 | Laboratorio Avi-Mex, S.A. De C.V. | Vacuna recombinante contra covid-19 en vector viral |
CN112011521A (zh) * | 2020-06-15 | 2020-12-01 | 浙江迪福润丝生物科技有限公司 | 一种重组新城疫病毒载体新型冠状病毒疫苗候选株及其构建方法和应用 |
-
2021
- 2021-01-08 PE PE2021000033A patent/PE20210318A1/es unknown
- 2021-12-28 AR ARP210103681A patent/AR124522A1/es unknown
-
2022
- 2022-01-04 BR BR112022016492A patent/BR112022016492A2/pt unknown
- 2022-01-04 WO PCT/IB2022/050031 patent/WO2022149058A1/es active Application Filing
- 2022-01-04 MX MX2022004220A patent/MX2022004220A/es unknown
- 2022-07-22 CO CONC2022/0010353A patent/CO2022010353A2/es unknown
- 2022-08-17 EC ECSENADI202264620A patent/ECSP22064620A/es unknown
Also Published As
Publication number | Publication date |
---|---|
PE20210318A1 (es) | 2021-02-16 |
BR112022016492A2 (pt) | 2023-10-31 |
WO2022149058A1 (es) | 2022-07-14 |
AR124522A1 (es) | 2023-04-05 |
MX2022004220A (es) | 2022-08-08 |
CO2022010353A2 (es) | 2022-08-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR065076A1 (es) | Vacuna contra el papilomavirus | |
CO6460752A2 (es) | Respuesta inmunitaria reforzada en especies aviares | |
PE20141482A1 (es) | Vectores recombinantes de hvt que expresan antigenos de patogenos de aves y sus usos | |
AR090469A1 (es) | Vacuna contra el virus sincicial respiratorio (rsv) | |
BRPI1015917A2 (pt) | antígenos de rsv recombinantes. | |
AR069882A1 (es) | Circovirus porcino, molecula de acido nucleico aislada que lo codifica, composicion inmunogenica que lo comprende, vector que comprende por lo menos una molecula de acido nucleico exogena que codifica una proteina de circovirus porcino y metodos para inmunizar un cerdo contra la infeccion virica o e | |
CY1120430T1 (el) | Ανασυνδυασμενες cdv συνθεσεις και χρησεις αυτων | |
CL2021003211A1 (es) | Una cepa viva modificada, del virus del síndrome respiratorio y reproductivo porcino (prrs), vacuna que lo comprende y su uso para tratar el prrs tipo ii. (divisional solicitud no. 2123-2018) | |
AR060565A1 (es) | Vacuna para la gripe aviaria y metodos de uso | |
BR112023005043A2 (pt) | Vacina contra covid-19 à base de piv5 | |
CL2017001961A1 (es) | Vacuna bivalente contra el virus de gripe porcina | |
AR109538A1 (es) | Vacuna contra la gripe porcina | |
PE20230171A1 (es) | Vacunas contra el coronavirus y metodos de uso | |
PE20170429A1 (es) | Vacuna en vector recombinante de adenovirus aviar serotipo 9 | |
AR094725A1 (es) | Parvovirus 5a porcino, métodos de uso y vacuna | |
BR112015022582A2 (pt) | molécula de ácido nucleico, plasmídeo, vacina, e, uso de um plasmídeo | |
AR103427A1 (es) | Vacuna contra la fiebre aftosa | |
CL2013002631A1 (es) | Virus de la necrosis pancreatica infecciosa (ipnv) avirulento porque comprende proteina vp2 madura. | |
RU2021112503A (ru) | Поливалентная вакцина против м. hyo и её применение | |
CO6700818A2 (es) | Vectores de parapoxvirus | |
EA202191145A1 (ru) | Вакцина виб 4/91 с гетерологичным шиповидным белком | |
BR112022019207A2 (pt) | Composições de vacina para coronavírus e métodos de uso das mesmas | |
ECSP22064620A (es) | COMPOSICIÓN INMUNOGÉNICA VIVA RECOMBINANTE QUE COMPRENDE EL VIRUS DE LA ENFERMEDAD DE NEWCASTLE (NDV) QUE EXPRESA LA SUBUNIDAD S1 Y EL RBD DE LA PROTEINA SPIKE DEL SARS-CoV-2 | |
AR105160A1 (es) | Métodos de modulación de moléculas de vigilancia de adn citosólicas | |
CO2023015564A2 (es) | Virus quimérico de la enfermedad de newcastle que expresa las proteínas hn y f del apmv |